Top news from MedWatch this week

Miss anything?

Photo: MedWatch


GN chair welcomes William Demant Invest

GN Hearing CEO denies debt challenges

Phony pharma tweet unleashes chaos – Eli Lilly, Novo Nordisk, and Sanofi stocks take hits

EMA holds its ground – certain obesity drugs must be removed from market

Costco contract unlikely to be renewed, Sonova hints

Sonova downgrades to lower end of guidance after difficult quarter


Ascendis Pharma submits drug candidate for European market approval

Ambu CEO heralds transition year after ”too optimistic” past predictions

GN chairman unsure about his board future

Coloplast stocks up on supplies for potential gas crisis

Sonova keeps options open for potential Costco contract

Novo Nordisk suspends Twitter advertising

Ambu plans transformation, targets 5–8% growth in 2022/2023


Ferring Pharmaceuticals and Gubra to collaborate on inflammatory bowel disease

US Inflation Reduction Act makes pharma market less attractive, says Novo CEO

Ambu halves pipeline to put quality over quantity

New long-term ambitions will be defined at later date, says Ambu CEO

Coloplast finds new president for Interventional Urology in own ranks


Lundbeck loses head of US organization

Genmab COO appointed to board of influential biotech association

US pharma industry urges official action against antimicrobial resistance


Novo Nordisk initiates trial of new candidate against fatty liver disease

Bavarian Nordic enters EU joint procurement deal for monkeypox doses

Abena in sustainability drive to make up for single-use products

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Latest news

See all jobs